They talk about us: Staying abreast of regulations with NGS-based viral safety for faster, safer and more ethical lot release of vaccines.
In this European Pharmaceutical Review article, Sridhar Pennathur, Vice President, Analytical Development at Novavax, highlights the value of next generation sequencing in their vaccine production operations by answering key questions.
PathoQuest announced the appointment of Michael Mellor-Clark as company CCO. Michael Mellor-Clark has more than 20 years of commercial experience in biosafety testing services
In her role as Sales Manager and NGS Specialist of PathoQuest site based in Paris, Mrs. Haifa Sghairi will further support the sales team and participate to the growth of the NGS-based solutions business for the biosafety of biologics markets.
Dr. Guillaume Deplaine has 10 years of experience in the Biotechnology industry. Prior to joining PathoQuest, Dr. Deplaine was the Quality Control and Analytical Development Head at CELLforCURE a CDMO specialized in CART Cells manufacturing, and was part of the Novartis Group.
Dr. Sébastien Renouf has 20 years of experience in Regulatory Affairs, Quality Assurance, and Safety Control for Cell & Gene Therapy. Before joining PathoQuest, Dr. Renouf was Chief Pharmaceutical Officer at CELLforCURE a CDMO specialized in the CART Cells manufacturing and part of the Novartis Group, where he supported the implementation of inspection and marketing authorization accreditation processes.
Interview with Colette Côté, Ph.D. : Chief Portfolio Officer and General Manager of PathoQuest’s U.S. subsidiary located in Wayne, PA.
A funny way to meet withMeet Colette Côté the Chief Portfolio Officer and General Manager of PathoQuest US subsidiary and, to understand how NGS solutions that identify adventitious agents using a rapid, animal-free, comprehensive testing approach can accelerate the development timelines of biologics.